Clinical Trials Logo

Clinical Trial Summary

Multicenter randomized double-blind study comparing the efficacy and safety of rituximab in combination with corticosteroids to corticosteroids plus placebo in the treatment of non-infectious active mixed cryoglobulinemia vasculitis.


Clinical Trial Description

Cryoglobulinemia are responsible for systemic vasculitis, and the most frequently targeted organs are the skin, joints, kidneys and peripheral nervous system. Cryoglobulinemia vasculitis are associated with significant morbidity and mortality, and require therapeutic intervention. Management of non-infectious mixed cryoglobulinemia vasculitis is based on corticosteroids, plasma exchange, and/or immunosuppressants. These treatments are associated with frequent side effects. To date, no study has evaluated the efficacy and safety of these different therapeutic options, explaining the lack of recommendations.

Rituximab, a monoclonal antibody directed against CD20, has emerged as a novel therapeutic option in B-cell related disorders. Data from the French AutoImmunity and Rituximab (AIR) registry recently reported the positive effect of rituximab in non-infectious mixed cryoglobulinemia vasculitis. More recently, the multidisciplinary national French CryoVas survey also suggested a significant superiority of the combination corticosteroid plus rituximab compared to the corticosteroids alone in terms of complete clinical and immunological responses and corticosteroid sparing. However, no randomized controlled data addressing this issue has been published to date. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02556866
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Terminated
Phase Phase 2
Start date July 17, 2015
Completion date May 31, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT02593565 - Vasculitis Pregnancy Registry
Terminated NCT01599260 - Resistance Exercise in Rheumatic Disease N/A
Terminated NCT01257802 - GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases Phase 3
Recruiting NCT05236491 - COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases Phase 2/Phase 3
Not yet recruiting NCT03514979 - Acquired Immunodeficiency in ANCA Associated Vasculitis Phase 2
Completed NCT02476292 - Impact of Vasculitis on Employment and Income N/A
Recruiting NCT03543527 - Study of Refractory and/or Relapsing TAkayasu aRTeritis
Completed NCT03762824 - Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Phase 4
Completed NCT03410290 - Journey of Patients With Vasculitis From First Symptom to Diagnosis
Completed NCT02042092 - Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS N/A
Active, not recruiting NCT01151644 - Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Phase 4